Australia's most trusted
source of pharma news
Saturday, 19 July 2025
Posted 17 July 2025 AM
Bayer is closing in on Astellas with its own non-hormonal therapy for menopause.
The German pharma scored its first worldwide nod for Lynkuet in the UK last week, signalling that the TGA, which began reviewing the once-daily oral treatment in September 2024 will make a similar decision soon.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.